PDCD1 and melanoma: T-cell reactivity against tumor neoantigens was subsequently demonstrated to underlie clinical responses to immunotherapies, such as CTLA-4 blockade in melanoma [181] and PD-1 blockade in non-small cell lung cancer [182].